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OBJECTIVE—The fatty acid translocase and scavenger recep-
tor CD36 is important in the recognition and uptake of lipids.
Accordingly, we hypothesized that it plays a role in saturated
fatty acid–induced macrophage lipid accumulation and proin-
ﬂammatory activation.
RESEARCH DESIGN AND METHODS—In vitro, the effect of
CD36 inhibition and deletion in lipid-induced macrophage in-
ﬂammation was assessed using the putative CD36 inhibitor,
sulfosuccinimidyl oleate (SSO), and bone marrow–derived mac-
rophages from mice with (CD36KO) or without (wild-type) global
deletion of CD36. To investigate whether deletion of macrophage
CD36 would improve insulin sensitivity in vivo, wild-type mice
were transplanted with bone marrow from CD36KO or wild-type
mice and then fed a standard or high-fat diet (HFD) for 20 weeks.
RESULTS—SSO treatment markedly reduced saturated fatty
acid–induced lipid accumulation and inﬂammation in RAW264.7
macrophages. Mice harboring CD36-speciﬁc deletion in hemato-
poietic-derived cells (HSC CD36KO) fed an HFD displayed im-
proved insulin signaling and reduced macrophage inﬁltration in
adipose tissue compared with wild-type mice, but this did not
translate into protection against HFD-induced whole-body insulin
resistance. Contrary to our hypothesis and our results using
SSO in RAW264.7 macrophages, neither saturated fatty acid–
induced lipid accumulation nor inﬂammation was reduced when
comparing CD36KO with wild-type bone marrow–derived mac-
rophages.
CONCLUSIONS—Although CD36 does not appear important in
saturated fatty acid–induced macrophage lipid accumulation, our
study uncovers a novel role for CD36 in the migration of proin-
ﬂammatory phagocytes to adipose tissue in obesity, with a con-
comitant improvement in insulin action. Diabetes 60:1100–
1110, 2011
O
besity is a key risk factor for the development
of insulin resistance leading to type 2 diabetes
and other metabolic pathologies. Obesity in-
duces a state of chronic, low-grade inﬂammation
that directly contributes to the development of insulin re-
sistance (1). The recruitment of proinﬂammatory macro-
phages to adipose tissue is central to this inﬂammatory
response. Accordingly, conditional deletion of CD11c
+
proinﬂammatory (M1) macrophages normalizes insulin
sensitivity and reduces inﬂammatory markers in diet-
induced obesity (2). Furthermore, mice that have a myeloid
deﬁciency in peroxisome proliferator–activated receptor-g,
and therefore an impaired ability to differentiate into alter-
natively activated anti-inﬂammatory macrophages (M2), are
predisposed to diet-induced obesity, inﬂammation, and in-
sulin resistance (3). Conversely, deletion of either inhibitor
of kB kinase (IKK) b or Jun NH2-terminal kinase (JNK),
critical regulators of inﬂammatory and cellular stress
responses (4), from myeloid cells or hematopoietic-derived
cells, respectively, can protect mice from obesity-induced
inﬂammation and insulin resistance (5,6).
Although the recruitment of proinﬂammatory macro-
phages and the consequent induction of adipose tissue
inﬂammation are important in the development of insulin
resistance, the upstream signals by which nutrient excess
trigger this response are unclear. A hallmark of obesity is
the intracellular accumulation of ectopic lipid and, in
particular, highly bioactive lipids such as diacylglycerols
(DAGs) and ceramide (7,8). Elevations in these inter-
mediates have been linked to inﬂammation and impaired
insulin action (9–11). Importantly, reducing macrophage
lipid accumulation decreases macrophage inﬂammation
and improves systemic insulin sensitivity (12,13).
The fatty acid translocase CD36 binds fatty acids and is
important for the uptake of lipids throughout the gastroin-
testinal tract (14), liver (15), myocardium, skeletal muscle,
and adipose tissue (16,17). Accordingly, CD36 polymor-
phisms and deﬁciencies in humans (18) and CD36 knockout
mice (17,19,20) are linked to perturbations in metabolism
and substrate utilization. In phagocytes, CD36 primarily
functions as a scavenger receptor, recognizing speciﬁcs e l f
and nonself molecular patterns and triggering internali-
zation and inﬂammatory signaling pathways to eliminate
pathogens and altered self components, such as apoptotic
cells (21). CD36 cooperates with toll-like receptor (TLR)-4
and -6 to mediate the sterile inﬂammatory response to al-
tered self components oxidized LDL (oxLDL) and amyloid-b
(22). CD36 also acts as a coreceptor with TLR2 and -6 in the
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ORIGINAL ARTICLErecognition of microbial diacylglycerides (23,24). Interest-
ingly, TLR4 recently has been suggested to mediate lipid-
induced inﬂammation (25,26). Given the pivotal roles of CD36
in both the recognition and uptake of lipids and its capacity to
induce inﬂammatory signaling in macrophages, we hypoth-
esized that hematopoietic cell–restricted deletion of CD36
would reduce lipid-induced macrophage inﬂammation and
improve obesity-induced metabolic perturbations.
RESEARCH DESIGN AND METHODS
Cell culture experiments. RAW264.7 macrophages were grown and pas-
saged in low-glucose Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% FBS, 100 units/mL penicillin, and 0.1 mg/mL streptomycin. Primary bone
marrow macrophages were derived from hind-limb bones of killed C57BL/6
(wild-type) and CD36KO mice at 6–12 weeks of age. Cells differentiated into
macrophages over 5–7 days in 20% conditioned media from L929 cells or
M-CSF (25 ng/mL). 3T3-L1 ﬁbroblasts were differentiated into adipocytes prior
to experiments, as previously described (27). Thioglycollate-elicited peritoneal
macrophages and primary adipocytes were isolated and differentiated as pre-
viously described (28).
All fatty acid treatments and overnight equilibration of cells were conducted
in Dulbecco’s modiﬁed Eagle’s medium, 3% FBS, and 2% fatty acid–free BSA
(Bovogen, Essendon, Australia). Macrophages were treated with sulfosucci-
nimidyl oleate (SSO) (500 mmol/L; A.Bon. and/or Anthem Biosciences,
Bangalore, India) or vehicle (DMSO) for 4 h prior to cotreatment with pal-
mitate (0.75 mmol/L; Sigma-Aldrich, St. Louis, MO), stearate (0.75 mmol/L;
Sigma-Aldrich), or vehicle (100% EtOH plus BSA) for an additional 4 h. For
conditioned-media studies, macrophages were only cotreated with SSO and
with palmitate for 2 h. Conditioned media collected over the following 4 h was
placed on 3T3-L1 adipocytes for 48 h, prior to the 30-min insulin (10 nmol/L;
Sigma-Aldrich) stimulation. Macrophages were treated with lipopolysaccha-
ride (LPS) (100 ng/mL, L8274; Sigma-Aldrich) or interferon (INF)-g (4 ng/mL;
R&D Systems) for the times indicated.
Bone marrow transplant and mouse procedures. Wild-type C57BL/6 and
CD36KO mice on a C57BL/6 background (29) were bred and housed at either
the Baker IDI Alfred Medical Research and Education Precinct Animal Facility
or an Association for Assessment and Accreditation of Laboratory Animal
Care–accredited facility at the Lerner Research Institute under a 12-h light/
dark cycle. All procedures were approved by the Alfred Medical Research and
Education Precinct Animal Ethics Committee or the Cleveland Clinic In-
stitutional Animal Care and Use Committee and were in accordance with the
National Health and Medical Research Council of Australia and with the Guide
for the Care and Use of Laboratory Animals published by the National
Institutes of Health.
To generate radiation chimeras, 6-week-old male mice were given bone
marrow transplants, as per Solinas et al. (5). Following 6 weeks of recovery,
chimeras were either maintained on a normal standard diet (14.3 MJ/kg en-
ergy, containing 8% calories from fat, 21% from protein, and 71% from car-
bohydrate; Specialty Feeds, Glen Forrest, Australia) or switched to a high-fat
diet (HFD) (19 MJ/kg energy, 42% of calories from fat [lard], 20% from protein,
and 35% from carbohydrate; Specialty Feeds) for 20 weeks. Prior to proce-
dures and blood collection, mice were fasted for 6 h. For the intraperitoneal
glucose tolerance test and intraperitoneal insulin tolerance test, glucose (1.0
g/kg lean body mass [LBM]) or insulin (0.75 units/kg LBM), respectively, was
injected. Tail blood was taken at indicated time points, and glucose was
measured using a human ACCU-CHEK blood monitor and test strips (Roche,
Basel, Switzerland). LBM and fat mass were assessed fortnightly using the
four-in-one EchoMRI body composition analyzer (Columbus Instruments,
Columbus, OH). Metabolic data were collected over 24 h using the Compre-
hensive Laboratory Animal Monitoring System (Columbus Instruments) after
an initial 2-h acclimatization. Following experimentation, mice were anes-
thetized (80 mg/kg sodium pentobarbital) and tissues excised before and after
the insulin injection (1.0 units/kg LBM) into the inferior vena cava.
Western blotting and lipid analysis. Cells were lyzed and tissues homoge-
nized as previously described (30). Protein was determined using the Micro
BCA Protein Assay Kit (no. 23235; Thermo Scientiﬁc, Rockford, IL) and boiled
in Laemelli’s buffer for 5 min. Protein was resolved by SDS-PAGE, transferred
to a nitrocellulose membrane, blocked in 5% milk, and incubated overnight
with primary antibody. Phosphorylated-JNK (Thr
183/Tyr
185), phosphorylated–
c-jun (Ser
73), JNK, phosphorylated-IKKb (Ser
181), IKKb, tumor necrosis factor
(TNF) a, phosphorylated-Akt (Ser
473) and (Thr
308), Akt, phosphorylated-IRb
(Tyr
1361), IRb,a n db-actin were obtained from Cell Signaling Technology;
a-tubulin was from Sigma-Aldrich; and CD36 was from R&D Systems. Fol-
lowing incubation with the appropriate horseradish peroxidase–conjugated
secondary antibody, proteins were detected with the ECL Advance Western
Blotting Detection Kit (GE Healthcare, Buckinghamshire, U.K.) and visualized
using the Molecular Imager ChemiDoc System (Bio-Rad Laboratories, Her-
cules, CA), and band volumes were quantiﬁed using Quantity One 1-D Analysis
Software 4.5.2. Initially, ceramide and diacylglycerols were assessed via thin-
layer chromatography, and additional lipid measurements were made via mass
spectrometry; both methods have been previously described (31,32).
Real-time PCR. Epididymal white adipose tissue (WAT) and liver were ho-
mogenized in 1.0 mL TRIzol reagent (Invitrogen, Mulgrave, Australia); RNA
was extracted according to the manufacturer’s instructions, DNAse treated
using DNase 1 (Invitrogen, Mulgrave, Australia), transcribed, and converted
to cDNA using TaqMan reverse transcription reagents (Applied Biosystems,
Foster City, CA). Gene expression analysis was performed using SYBR Green
PCR Mastermix (Applied Biosystems, Warrington, U.K.) or TaqMan gene ex-
pression assays (Applied Biosystems), including 18S probe and primers for
housekeeping measurements.
Genomic PCR. DNA was extracted from whole blood using Maxwell Whole
BloodPuriﬁcationKitsandtheMaxwell 16Instrument(Promega,Madison,WI).
Speciﬁc primers yielded PCR products of 600 bp (wild-type) and 750–800 bp
(CD36KO).
Multianalyte plasma proﬁling. Plasma chemokine (C-C motif) ligand 2
(CCL2)/monocyte chemotactic protein (MCP)-1, interleukin (IL)-6, IL-1b,I N F - g,
IL-4, and IL-10 were measured using a ﬂuorokine mouse multianalyte proﬁling
kit (R&D Systems, Minneapolis, MN) and read using a BioPlex system (Bio-Rad
Laboratories).
Flow cytometry. Six weeks after the bone marrow transplant, blood collected
from Ly5.1 and Ly5.2 mice was stained with anti–CD45.2-ﬂuorescein iso-
thiocyanate (Ly5.2) and anti–CD45.1-phycoethrin (Ly5.1) antibodies or appro-
priate isotype controls (BD Biosciences, San Jose, CA). Erythrocytes were lyzed
using FACS Lyzing Solution (BD Biosciences). White blood cells were ana-
lyzed via a FACSCalibur (BD Biosciences) ﬂow cytometer using CellQuest Pro
software.
Hormone and cytokine analysis. Fasting plasma insulin was determined
using a rat/mouse insulin ELISA kit (Millipore, Billerica, MA). TNFa was de-
termined using a DuoSet ELISA Development System (R&D Systems) for
mouse TNFa.
Immunohistochemistry. Paraformaldehyde-ﬁxed, parafﬁn-embedded, epi-
didymal WAT was deparafﬁnized and rehydrated in histoline and alcohol and
stained with Mayer’s hematoxylin and eosin and analyzed using Image-Pro
Plus (6.0) software. For immunostaining, sections were boiled in sodium
citrate buffer and blocked in 3% hydrogen peroxide, incubated in F4/80 anti-
body (1:100 dilution; AbD Serotec, Kidlington, U.K.) overnight at 4°C using
an M.O.M. Immunodetection Kit (Vector Laboratories, Burlingame, CA), in-
cubated with biotinylated anti-rat IgG and then with avidin-biotin peroxidase
complex and DAB peroxidase substrate (Vector Laboratories), and, ﬁnally,
stained with Mayer’s hematoxylin and dehydrated.
Binding and migration assay. A migration assay was conducted as previously
described (28). Brieﬂy, conditioned media was collected from primary adi-
pocytes and treated for 12 h with vehicle, oxLDL, or advanced glycation end
product (AGE)-BSA; washed with PBS; and incubated with serum-free media
for 8 h. Wild-type and CD36KO peritoneal macrophages were loaded into the
migration chamber with adipocyte-conditioned media. Sixteen hours later,
nuclei of migratory cells were stained and counted. For the binding assay,
peritoneal macrophages were plated onto treated tissue-culture plastic
(Corning) at 0.5 3 10
6 cells per mL and placed on an orbital shaker at 60 rpm
for 18 h, with vehicle, NO2LDL, or MCP-1. Plates were washed and macro-
phages labeled with 2.5 mmol/L PKH dye in diluent B (Sigma) for 5 min at
room temperature, washed again, and analyzed using a ﬂuorescent microplate
reader (Gemini EM; Molecular Devices) (551 nm excitation, 567 nm emission).
Statistical analysis. Data are expressed as means 6 SE. ANOVA with re-
peated measures or the Student t test were performed using SigmaStat (ver-
sion 3.5), where appropriate (see ﬁgure legends). A P value of ,0.05 denoted
statistical signiﬁcance.
RESULTS
The putative CD36 inhibitor SSO prevents saturated
fatty acid–induced lipid accumulation and macrophage
inﬂammation, resulting in improved insulin signaling
in adipocytes. To investigate the role of CD36 in saturated
fatty acid–induced macrophage activation, we inhibited
CD36 using SSO, a CD36 inhibitor shown to cross-link CD36
on the cell membrane and prevent lipid transport (33).
RAW264.7 macrophages were pretreated with or without
SSO before being treated with the saturated fatty acids
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duced phosphorylation of the stress-activated serine threo-
nine kinase JNK, its substrate c-jun, and IKKb (Fig. 1A and
B) and stimulated the secretion of TNFa (Fig. 1C). These
effects were reduced in macrophages pretreated with SSO
(Fig. 1A–C). Both palmitate and stearate increased cer-
amide and DAG accumulation in RAW264.7 macrophages
(Fig. 1D and E)a n dp r i m a r yb o n em a r r o w –derived mac-
rophages (BMDMs) (Supplementary Fig. 1A and B), an ef-
fect that was largely prevented by SSO (Fig. 1D and E;
Supplementary Fig. 1A and B). These data suggested that
CD36 was involved in the uptake of long-chain saturated fatty
acids into macrophages. Adipose tissue macrophages se-
crete proinﬂammatory molecules that interfere with adipocyte
FIG. 1. The putative CD36 inhibitor SSO prevents saturated fatty acid–induced lipid accumulation and macrophage inﬂammation, resulting in
improved insulin signaling in adipocytes. RAW264.7 macrophages were incubated with vehicle or the putative CD36 inhibitor SSO for 4 h then
with either BSA (vehicle) or the saturated fatty acids palmitate (16:0) or stearate (18:0) for an additional 4 h. Cellular extracts were analyzed
for phosphorylated (p) (Thr
183/Tyr
185)J N K( A), its substrate phosphorylated (Ser73) c-jun total JNK (B), and phosphorylated (Ser
181)I K K b (C)
by Western blotting. TNFa released into the media was measured by ELISA. Total ceramide (D)a n dD A G( E) were extracted and quantiﬁed via
thin-layer chromatography. F: To obtain conditioned media, RAW264.7 macrophages were incubated with vehicle or SSO overnight then with BSA
(vehicle) or palmitate (Palm) for 2 h and then palmitate/BSA-free media for 4 h. This conditioned media, or nonconditioned control media (Con),
was incubated with differentiated 3T3-L1 adipocytes for 48 h before insulin stimulation. Cellular extracts were analyzed for phosphorylated (p)
(Ser
473) Akt and total Akt. TNFa released into the conditioned media was measured via ELISA (inset). Data shown are from one experiment,
representative of two to four independent experiments, expressed as means 6 SE (n =3 ) .A–E and F, inset:* P < 0.05 fatty acid vs. BSA; **P <
0.001 fatty acid vs. BSA; #P < 0.05 SSO vs. vehicle; ##P < 0.001 SSO vs. vehicle. F:* * P < 0.001 insulin stimulated vs. control insulin stimulated;
#P < 0.05 palmitate conditioned media insulin stimulated vs. palmitate plus SSO conditioned media insulin stimulated; two-way ANOVA with post
hoc analysis.
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RAW264.7 macrophages, we investigated whether SSO
treatment of macrophages could improve insulin signaling
in 3T3-L1 adipocytes. Conditioned media from both control
BSA and palmitate-treated macrophages reduced insulin-
stimulated phosphorylation of Akt, a critical mediator of
insulin signaling, compared with control cells with normal
medium (Fig. 1F). Pretreating macrophages with SSO re-
duced TNFa secretion into conditioned media and increased
Akt phosphorylation in adipocytes treated with palmitate-
conditioned media (Fig. 1F, inset). These data suggested
that targeting CD36 in myeloid cells, in settings of lipid
oversupply, could be a viable strategy to attenuate insulin
resistance in adipose tissue in vivo.
Hematopoietic deletion of CD36 reduces macrophage
content and improves insulin signaling in adipose
tissue of mice fed an HFD. In the context of obesity-
induced inﬂammation and insulin resistance, macrophages
play an important role in the adipose tissue (1). We hypo-
thesized that hematopoietic deletion of CD36 would im-
prove whole-body insulin sensitivity via effects on adipose
tissue. To this end, we transplanted lethally irradiated wild-
type mice with bone marrow from CD36KO or background-
matched (C57BL/6) wild-type mice to create chimeras whose
hematopoietic-derived cells were deﬁcient in CD36, desig-
nated wild-type or CD36KO, respectively. Consistent with
previous reports (5,34), we show ~95% reconstitution of bone
marrow as assessed by ﬂow cytometry (Supplementary
Fig. 2A). In addition, we also PCR genotyped experimental
mice at the completion of the study (26 weeks after bone
marrow transplant) and conﬁrmed reconstitution of do-
nor bone marrow in the CD36KO animals (Supplementary
Fig. 2B). Following 6 weeks of recovery, mice either con-
tinued on a normal standard diet or were placed on an HFD
for 20 weeks. To assess macrophage content of adipose
tissue, we determined the mRNA expression of the macro-
phage markers F4/80 (Emr1), CD11c (Itgax), and chemo-
kine (C-C motif) ligand 2 (Ccl2). The expression of emr1,
itgax,a n dccl2 in adipose tissue of mice fed an HFD was
markedly elevated relative to the standard diet–fed mice
(Fig. 2A). Importantly, the expression of emr1 was signiﬁ-
cantly lower, and itgax and ccl2 also tended to be lower, in
CD36KO mice compared with wild-type mice fed an HFD
(Fig. 2A). To conﬁrm that CD36KO mice had reduced
macrophage content within the adipose tissue, we per-
formed immunohistochemistry and enumerated the
number of F4/80-positive crown-like structures present in
adipose tissue cross-sections. The numbers of crown-like
structures present in HFD-fed CD36KO mice were sub-
stantially reduced relative to wild-type control mice (Fig. 2B
and Supplementary Fig. 2C).
To assess the inﬂammatory proﬁle of the adipose tissue,
we performed gene expression analysis for markers of
both proinﬂammatory (M1) and alternative/remodelling
(M2) macrophages. The expression of arginase 1 (Arg1),
an M2 macrophage marker, was signiﬁcantly higher in the
adipose tissue of CD36KO mice compared with wild-type
mice (Fig. 2C). Correspondingly, we observed a trend for
reduced mRNA expression of cytokines produced pri-
marily by M1 macrophages (e.g., tnfa and il6), as well as
the Th1 cytokine ifng, when comparing HFD-fed CD36KO
and wild-type mice (Fig. 2C). We did not observe any dif-
ferences in the mRNA expression of the anti-inﬂammatory
cytokine IL-1 receptor antagonist (Il1rn), neither were
there any differences in JNK phosphorylation in adipose
tissue when comparing wild-type and CD36KO mice fed an
HFD (Supplementary Fig. 2D–F).
Emr1 and itgax mRNA expression in the liver of mice
fed an HFD were increased relative to standard-diet–
fed mice, indicating kupffer cell accrual. Similarly, ccl2
mRNA expression was signiﬁcantly elevated; no signiﬁcant
changes in the expression of tnfa, il1b, ifng, il6,o ril10
were observed in mice fed an HFD compared with standard-
diet–fed mice (Supplementary Fig. 2F and data not shown).
These data suggest that the role of CD36 in macrophage
accrual is restricted to the adipose tissue.
Next, we determined whether the reduced macrophage
accumulation observed in CD36KO mice, relative to wild-
type mice on an HFD, resulted in altered adipose tissue
insulin sensitivity. Insulin failed to stimulate phosphoryla-
tion of the insulin receptor (IR) in the wild-type mice fed
an HFD, but increased insulin-stimulated IR phosphoryla-
tion was observed in CD36KO mice (Fig. 2D). Further-
more, although insulin-stimulated Akt phosphorylation
at Thr
308 and Ser
473 was reduced in HFD relative to
standard diet–fed mice, insulin-stimulated Akt phosphory-
lation was signiﬁcantly increased in CD36KO mice com-
pared with wild-type mice on an HFD (Fig. 2E and F).
Hematopoietic deletion of CD36 does not affect body
weight or whole-body insulin sensitivity. Next, we ex-
amined whether hematopoietic cell–restricted deletion of
CD36 altered whole-body adiposity and/or insulin action.
There were no differences in the total body weight or
percentage of body fat between wild-type and CD36KO
mice at any time during the 20-week dietary intervention
(Fig. 3A and B). Furthermore, neither epididymal WAT
weight nor adipocyte size or number was different when
comparing the CD36KO with wild-type mice after 20 weeks
of either standard diet or high-fat feeding (Supplementary
Fig. 3A and B and data not shown). This ﬁnding is con-
sistent with others that show unaltered adiposity despite
improvements in adipose tissue insulin sensitivity (35).
As expected, HFD-fed mice became progressively hyper-
insulinemic and hyperglycemic compared with standard
diet–fed animals (Fig. 3C and D). Although fasting glucose
was higher in the CD36KO mice compared with wild-type
mice fed a standard diet at 4 weeks, no differences in plasma
insulin were observed on either the standard diet or HFD at
a n yt i m ep o i n tm e a s u r e d( F i g .3 C and D). We performed
glucose and insulin tolerance tests at the end of the 20-week
dietary period. As expected, mice fed an HFD displayed
impaired glucose (Fig. 3E) and insulin (Fig. 3F) tolerance
compared with standard diet–fed mice; however, no differ-
ences were observed when comparing CD36KO and wild-
type mice on either diet (Fig. 2E and F).
Adipose tissue inﬂammation and insulin resistance can
result in systemic insulin resistance via the secretion of
inﬂammatory cytokines/adipokines that, in turn, alter in-
sulin action in other peripheral tissues, such as liver and
skeletal muscle (4,13). We measured a number of circu-
lating cytokines/adipokines via multianalyte plasma pro-
ﬁling and found no differences in any measurements when
comparing plasma taken from CD36KO or wild-type mice
fed an HFD for 19 weeks (data not shown). Accordingly,
there were no differences in insulin-stimulated Akt phos-
phorylation between the CD36KO and wild-type mice on
an HFD in either the liver or skeletal muscle (data not
shown). We observed no differences in food intake, oxy-
gen consumption, respiratory exchange ratio, or activity
levels when comparing CD36KO with wild-type mice on
either the standard diet or the HFD (data not shown).
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diabetes.diabetesjournals.org DIABETES, VOL. 60, APRIL 2011 1103FIG. 2. Hematopoietic deletion of CD36 reduces macrophage content and improves insulin signaling in adipose tissue of mice fed an HFD. Mice with
hematopoietic-speciﬁc deletion of CD36 (CD36KO) were created by bone marrow transplanting stem cells from CD36KO or background-matched
wild-type (WT) mice into lethally irradiated C57BL/6 mice. After 20 weeks of the standard diet or HFD, epididymal WAT depots were excised
before and after insulin stimulation. A: Gene expression of F4/80 (Emr1), CD11c (Itgax), and ccl2 in the WAT of WT and CD36KO mice on an HFD
was measured by real-time PCR, expressed relative to WT standard diet–fed mice indicated by the dotted line. B: Immunohistochemical staining for
F4/80 (brown staining, see arrow) in WAT sections from WT and CD36KO mice on an HFD. The percentage of adipocytes with crown-like structures
(CLS) was determined for both WT and CD36KO mice on an HFD (6–10 images at 320 magniﬁcation were analyzed per mouse). C: Gene expression
of the alternative macrophage activation (M2) marker, arginase 1 (Arg1), and inﬂammatory cytokines tnfa, il6,a n difng in the WAT of WT and
CD36KO mice were measured by real-time PCR, expressed relative to WT standard diet–fed mice, indicated by the dotted line. WAT from basal and
insulin-stimulated WT and CD36KO mice fed a standard diet and HFD were analyzed for phosphorylated (p) (Tyr
1361) and total IR (D) and
phosphorylated (p) (Ser
473 and Thr
308) and total Akt (E and F) by Western blotting. Data are expressed as means 6 SE (n =6 –8 mice per group).
*P < 0.05 insulin stimulated vs. basal; **P < 0.001 insulin stimulated vs. basal; #P < 0.05 CD36KO vs. WT; ##P < 0.001 CD36KT; Student t tests and
two-way ANOVA with post hoc analysis. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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1104 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgFIG. 3. Hematopoietic deletion of CD36 does not affect body weight or whole-body insulin sensitivity. Radiation chimeras with hematopoietic
deletion of CD36 (HSC CD36KO) and control mice (WT) were placed on either an HFD or normal standard diet for 20 weeks. Total body mass (A)
and percent fat mass (B) were assessed every fortnight over the dietary intervention using EchoMRI. At the weeks indicated, fasting insulin (C)
and glucose (D) levels in the plasma were assessed via ELISA and glucometer, respectively. Intraperitoneal glucose (E) and insulin tolerance (F)
tests were conducted at 20 weeks. □, WT standard diet; ○, HSC CD36KO standard diet; ■, WT HFD; ●, HSC CD36KO HFD. Area under the curve is
displayed in the inset. All data are expressed as means 6 SE (n =6 –8). *P < 0.05 HFD vs. standard diet; **P < 0.001 HFD vs. standard diet; #P <
0.05 WT vs. HSC CD36KO; ^P < 0.05 different to week 4; ^^P < 0.001 different to week 4; two-way repeated-measures ANOVA, where appropriate,
and two-way ANOVA with post hoc analysis.
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despite enhanced adipose tissue insulin signaling and a re-
duction in adipose tissue inﬂammation, are not protected
from the development of HFD-induced insulin resistance.
CD36KO BMDMs are not protected from saturated
fatty acid–induced lipid accumulation. The putative
CD36 inhibitor SSO prevented lipid accumulation in mac-
rophages. Moreover, adipose tissue macrophage recruit-
ment and insulin signaling were improved in HFD-fed mice
with a hematopoietic-speciﬁcd e ﬁciency in CD36, com-
pared with wild-type mice. To further explore these ﬁnd-
ings at the cellular level, we examined whether genetic
deletion of CD36 from macrophages prevented lipid ac-
cumulation and resultant inﬂammation. Accordingly, we
treated bone marrow–derived wild-type and CD36KO mac-
rophages with palmitate and stearate. In contrast to phar-
macological inhibition of CD36 using SSO (see Fig. 1),
CD36KO macrophages accumulated triacylglycerol, DAG,
and ceramide to the same extent as wild-type macro-
phages (Fig. 4A–C). When CD36KO macrophages were
treated with SSO, the reduction in the accumulation of
ceramide and DAG was comparable with that seen in wild-
type macrophages (Fig. 4D and E). These results demon-
strate that the intracellular accumulation of these lipids is
not dependent on CD36, and, therefore, in macrophages,
CD36 does not appear to act as a lipid transporter. In ad-
dition, this highlights that SSO prevents lipid accumulation
in BMDM in a CD36-independent manner.
CD36KO BMDMs show a blunted proinﬂammatory
response to LPS and INF-g but not palmitate. Con-
sistent with the lack of effect of CD36 deletion on satu-
rated fatty acid uptake in BMDMs, we observed that
increasing concentrations of palmitate induced JNK and
IKKb phosphorylation to the same extent in CD36KO and
wild-type macrophages (Fig. 5A and B). CD36 has been
shown to cooperate with TLR4 to promote sterile in-
ﬂammation (22), and TLR4 is implicated in lipid-induced
inﬂammation (36). Therefore, we investigated whether
the absence of CD36 blunted inﬂammatory responses to
LPS, a TLR4 ligand. Deletion of CD36 did not prevent the
phosphorylation of JNK in response to LPS (Supplementary
Fig. 4). However, LPS-induced il6 and tnfa gene expression
were blunted in CD36KO BMDMs compared with wild-type
controls (Fig. 5C). Gene expression of il6 and il1b in re-
sponse to INF-g also was blunted in CD36-deﬁcient BMDMs.
These results suggest that although CD36 may not play an
important role in the promotion of saturated fatty acid–
induced macrophage activation, it is important in regulating
responses to other proinﬂammatory stimuli.
CD36KO peritoneal macrophages do not migrate in
response to adipocyte-derived chemotactic factors.
Because HFD-fed hematopoietic stem cell (HSC) CD36KO
mice accumulate less macrophages than wild-type mice,
we inferred that CD36 may be important in macrophage
migration and, accordingly, conducted an in vitro migration
assay. Conditioned media was collected from primary adi-
pocytes, which were either untreated (control) or stimulated
with oxLDL or AGEs to release chemotactic cytokines. Wild-
type and CD36KO macrophages were placed in wells with
a porous membrane and incubated with conditioned media.
Both treatments increased the migration of wild-type mac-
rophages through the porous membrane; however, this was
blunted in CD36KO macrophages (Fig. 6A). In addition,
CD36KO macrophages also showed reduced migration to
FIG. 4. CD36KO BMDMs are not protected from saturated fatty acid–induced lipid accumulation. Bone marrow–derived macrophages from wild-
type (WT) and CD36KO mice were treated with the saturated fatty acids palmitate (16:0), stearate (18:0), or BSA (control) for 4 h, with or
without pretreatment with the putative CD36 inhibitor SSO (0.5 mmol/L, 4 h). Total triacylglycerol (TAG) (A), total ceramide (B and E), DAG
species 16:0 (C), and the sum of 16:0 and 18:0 DAGs (D) were extracted and analyzed via electrospray ionization-tandem mass spectrometry. All
data are expressed as means 6 SE (n =3 –6, data shown are from one experiment, representative of two independent experiments). **P < 0.001
fatty acid vs. BSA vehicle; #P < 0.05 vehicle vs. SSO; ##P < 0.001 vehicle vs. SSO; two-way ANOVA with post hoc analysis. Palm, palmitate; Ste,
stearate; Veh, vehicle.
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with wild-type macrophages.
Because CD36 is a scavenger receptor important in the
recognition of oxLDL, bacterial proteins, and apoptotic
cells (37), we proposed that CD36KO macrophages may
have altered binding capacity. Indeed, compared with
wild-type macrophages, the binding of CD36KO macro-
phages to plastic in response to oxLDL or MCP-1 was
blunted (Fig. 6B). Together with the ﬁnding that mice with
hematopoietic-speciﬁc deletion of CD36 have reduced
macrophage accumulation into expanded adipose tissue,
these results argue that CD36 is important in obesity-
induced macrophage recruitment into adipose tissue.
DISCUSSION
We hypothesized that hematopoietic cell–restricted deletion
of CD36 would ameliorate obesity-induced inﬂammation
and insulin resistance, potentially via the inhibition of fatty
acid uptake into macrophages and/or via the inhibition of
fatty acid–induced signaling pathways. In partial support of
this hypothesis, HSC deletion of CD36 improves insulin
action in adipose tissue of mice fed an HFD. Concomitantly,
we observed a marked reduction in macrophage recruit-
ment and a tendency toward a reduction in the inﬂam-
matory proﬁle of WAT. However, these improvements did
not result in improved whole-body insulin sensitivity. Sur-
prisingly, we found that CD36 is not required for the uptake
or the proinﬂammatory effects of long-chain saturated fatty
acids in macrophages; however, it is likely involved in their
migration to adipose tissue in obesity. In addition, our re-
sults strongly argue that SSO, thought to be a speciﬁci n -
hibitor of CD36, blocks lipid accumulation and inﬂammation
in BMDMs in a CD36-independent manner.
Because HFD-fed mice with a hematopoietic-speciﬁcd e -
letion of CD36 show reduced recruitment of proinﬂammatory
macrophages into adipose tissue, this suggests that CD36
plays a role in monocyte recruitment to inﬂammatory tissues.
In vitro, CD36KO macrophages have a reduced migratory
capacity when incubated with adipose-derived chemotactic
FIG. 5. CD36KO BMDMs show a blunted proinﬂammatory response to LPS and INF-g but not palmitate. Bone marrow–derived macrophages from
wild-type (WT) and CD36KO mice were treated with increasing concentrations of the saturated fatty acid palmitate (16:0) or BSA (vehicle) for 4 h.
Cellular extracts were analyzed for phosphorylated (p) (Thr
183/Tyr
185) and total JNK, CD36, b-actin (A) and phosphorylated (p) (Ser
181) and
total IKK (B) by Western blotting. Bone marrow–derived macrophages from WT and CD36KO mice were treated with LPS (C) or INF-g (D)f o r6h
and gene expression of TNFa, IL-6, and IL-1b were assessed by real-time PCR. All data are expressed as means 6 SE. A and B: n =3 –9, data are the
combination of three independent experiments. C and D: n = 6, data are from one experiment. *P < 0.05 treatment vs. vehicle; **P < 0.001
treatment vs. vehicle; #P < 0.05 WT vs. CD36KO; ##P < 0.001 WT vs. CD36KO; two-way ANOVA with post hoc analysis.
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CD36/apolipoprotein E double-knockout mice show reduced
spreading in response to the adipose-derived chemotactic
cytokine CCL2 in in vitro migration assays (38,39). Two ad-
ditional reports also identify a role for CD36 in the regulation
of monocyte migration to sites of vascular inﬂammation
(40,41). Thus, we propose that CD36 is important in the re-
cruitment of monocytes/macrophages to sites of inﬂam-
mation and contributes to obesity-induced adipose tissue
inﬂammation.
Adipose tissue remodeling and associated adipocyte
cell death in obesity is a dynamic process that has been
linked to macrophage recruitment and adipose tissue in-
ﬂammation (42,43). CD36 is implicated in recognition of
cellular apoptotic markers, such as oxidized phosphati-
dylserine, and clearance of apoptotic cells (44). CD36 de-
letion in macrophages may limit macrophage recruitment
into the adipose tissue because of their inability to recog-
nize apoptotic adipocytes.
Our data suggest that although strategies that reduce
macrophage recruitment into adipose tissue may reduce
adipose tissue inﬂammation and improve adipocyte insulin
sensitivity, these effects in isolation may not be sufﬁcient
to improve insulin action in other tissues. This view is
consistent with other studies, where the inactivation of
JNK1 (a serine kinase with important roles in proin-
ﬂammatory signaling) in hematopoietic cells was not suf-
ﬁcient to signiﬁcantly affect systemic insulin sensitivity in
mice on an HFD (35,45), despite signiﬁcant reductions in
adipose-derived cytokines (45). Altogether, it is possible
that the contribution of adipose tissue macrophages to
obesity-induced systemic metabolic deregulation may be
limited.
Alternatively, it is possible that bone marrow ablation of
CD36 is not sufﬁcient to improve systemic insulin sensi-
tivity because its effect on adipose tissue macrophage re-
cruitment and proinﬂammatory adipokines is partial and
a more potent intervention on adipose tissue macrophages
could lead to signiﬁcant systemic effects on glucose ho-
meostasis. Consistent with this view, both complete ab-
lation of activated adipose tissue macrophages (2) or
hematopoietic-speciﬁc deletion of the lipid chaperone aP2
(13) is sufﬁcient to normalize, or improve, insulin sensi-
tivity in HFD-fed mice, respectively.
Because neither ceramide nor DAG accumulation was
reduced in CD36KO macrophages treated with saturated
fatty acids, it seems that CD36 itself is not critical in the
transport or trafﬁcking of saturated fatty acids into mac-
rophages. It is unequivocal that CD36 plays an important
role in the uptake of long-chain fatty acids into adipocytes,
cardiac and skeletal myocytes, and other tissues (16,17).
Other transport proteins, such as the lipid chaperone fatty
acid–binding protein 4 (aP2), are likely to play a more
critical role in macrophage lipid accumulation (13).
CD36 has gained considerable attention recently as
a pattern-recognition receptor and coreceptor for speciﬁc
TLRs (i.e., TLR2, -4, and -6) (22,23). In this regard, it is of
interest to note that TLR4 has been suggested to sense
lipids and may provide a link between dyslipidemia and
obesity-induced inﬂammation (36). Although LPS-induced
JNK activation was unaltered in CD36KO macrophages,
expression of the proinﬂammatory genes il6 and tnfa were
markedly reduced. These data argue a role for CD36 in
mediating TLR4-dependent signaling and priming macro-
phages to take on a more proinﬂammatory (M1) pheno-
type. Given that palmitate-induced inﬂammatory signaling
was unaffected by the absence of CD36 in macrophages, it
is unlikely that CD36 cooperates with TLRs in their pos-
sible role as lipid sensors.
Our initial ﬁndings using the putative CD36 inhibitor
SSO led us to hypothesize a role for CD36 in lipid transport
in macrophages. However, the ﬁnding that SSO reduced
ceramide and DAG accumulation in CD36KO BMDMs
suggests that SSO is affecting lipid metabolism and in-
ﬂammation in a CD36-independent manner. In support of
this notion, it has previously been reported that SSO binds
to the mitochondrial membrane and alters mitochondrial
oxidation rates independently of CD36 (46). Although we
do not know how SSO prevented lipid accumulation and
inﬂammation in macrophages, our ﬁndings suggest that
results obtained with SSO, in particular cell types, should
be interpreted with caution.
In conclusion, although CD36 does not appear to be
important in saturated fatty acid–induced macrophage
lipid accumulation, or in directly mediating the proin-
ﬂammatory effects of lipids, our study uncovers a novel
role for CD36 in the migration of proinﬂammatory phag-
ocytes into adipose tissue during diet-induced obesity.
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